Cancer therapy. Setbacks for endostatin.
Marshall
Eliot
E
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D003094:Collagen / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology* / Q000627:therapeutic use; D043169:Endostatins; D005354:Fibrosarcoma / Q000098:blood supply / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology* / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D015203:Reproducibility of Results
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins; D010446:Peptide Fragments; D003094:Collagen